Anaptysbio (ANAB) Total Non-Current Liabilities (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Total Non-Current Liabilities data on file, last reported at $65.9 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 28.07% year-over-year to $65.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.9 million (down 28.07% YoY) and the FY2025 annual result came in at $87.9 million, down 32.62% from the prior year.
• Total Non-Current Liabilities fell to $65.9 million in Q1 2026, from $87.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $583.5 million in Q3 2022 to a low of $3.9 million in Q2 2025.
• A 5-year average of $180.9 million and a median of $141.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The widest YoY moves for Total Non-Current Liabilities: up 4.16% in 2025, down 94.05% in 2025.
• Tracing ANAB's Total Non-Current Liabilities over 5 years: stood at $306.0 million in 2022, then slumped by 53.73% to $141.6 million in 2023, then decreased by 7.89% to $130.4 million in 2024, then sank by 32.62% to $87.9 million in 2025, then fell by 24.95% to $65.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $65.9 million (Q1 2026), $87.9 million (Q4 2025), and $21.3 million (Q3 2025), per Business Quant data.